Michael Burkes Brophy Sells 784 Shares of Natera (NASDAQ:NTRA) Stock

January 30, 2026 by InsiderTrades.com

Key Points

CFO Michael Burkes Brophy sold 784 shares of Natera on Jan. 27 at an average price of $240.53 for $188,575.52, leaving him with 63,339 shares (a 1.22% reduction in that reported holding).
Across Jan. 20–29 he sold multiple additional tranches (including sales of 37,175 and 23,948 shares), totaling 66,187 shares listed in the article and roughly $15.83 million in proceeds from those trades.
Other insiders (including CEO Steven L. Chapman) also sold late in January, while analysts maintain a consensus of “Moderate Buy” on Natera with an average target of $249.20; the stock recently traded near $231.48 within a 52-week range of $125.38–$256.36.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 784 shares of Natera stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $240.53, for a total transaction of $188,575.52. Following the completion of the transaction, the chief financial officer directly owned 63,339 shares in the company, valued at approximately $15,234,929.67. This represents a 1.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

3 Under-the-Radar Healthcare Companies

Michael Burkes Brophy also recently made the following trade(s):

On Thursday, January 29th, Michael Burkes Brophy sold 1,867 shares of Natera stock. The stock was sold at an average price of $230.40, for a total transaction of $430,156.80.
On Wednesday, January 28th, Michael Burkes Brophy sold 2,413 shares of Natera stock. The stock was sold at an average price of $237.56, for a total transaction of $573,232.28.
On Wednesday, January 21st, Michael Burkes Brophy sold 37,175 shares of Natera stock. The stock was sold at an average price of $242.54, for a total transaction of $9,016,424.50.
On Tuesday, January 20th, Michael Burkes Brophy sold 23,948 shares of Natera stock. The shares were sold at an average price of $234.74, for a total transaction of $5,621,553.52.

Natera Stock Performance

Natera stock opened at $231.48 on Friday. Natera, Inc. has a 52 week low of $125.38 and a 52 week high of $256.36. The firm has a market capitalization of $32.02 billion, a PE ratio of -101.08 and a beta of 1.62. The business's 50-day simple moving average is $235.90 and its 200-day simple moving average is $193.29.

Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The business had revenue of $592.18 million for the quarter, compared to the consensus estimate of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. Natera's revenue for the quarter was up 34.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.26) EPS. Research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera News Summary

Here are the key news stories impacting Natera this week:

Negative Sentiment: CFO Michael Burkes Brophy sold a total of 5,064 shares across Jan. 27–29 for roughly $1.19M (transactions at ~$240.53, $237.56 and $230.40); his holdings fell by ~3% but he still holds ~59k shares. CFO Form 4
Negative Sentiment: CEO Steven L. Chapman sold 5,970 shares across Jan. 27–28 for roughly $1.43M (avg ~$237–240); his stake decreased ~1–2% and he still owns ~213k shares. CEO Form 4
Negative Sentiment: Other insiders (John Fesko and Solomon Moshkevich) also sold multiple tranches (combined ~3,925 shares, ~ $0.94M), each reducing holdings by under 1%. Fesko Form 4 Moshkevich Form 4

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Canaccord Genuity Group reiterated a "buy" rating on shares of Natera in a research note on Monday, January 12th. Citigroup assumed coverage on shares of Natera in a report on Wednesday, January 7th. They set a "buy" rating and a $300.00 price objective on the stock. Zacks Research upgraded shares of Natera from a "strong sell" rating to a "hold" rating in a research note on Thursday, January 1st. Evercore ISI lifted their target price on Natera from $190.00 to $250.00 and gave the stock an "outperform" rating in a research report on Friday, November 7th. Finally, BTIG Research boosted their price target on Natera from $230.00 to $260.00 and gave the company a "buy" rating in a research note on Friday, December 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $249.20.

Read Our Latest Stock Report on NTRA

Institutional Trading of Natera

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Horizon Investments LLC acquired a new position in Natera in the third quarter worth about $32,000. Hilltop National Bank bought a new stake in shares of Natera in the 2nd quarter valued at approximately $33,000. Sound Income Strategies LLC raised its holdings in shares of Natera by 95.7% in the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company's stock worth $39,000 after buying an additional 110 shares in the last quarter. Flagship Harbor Advisors LLC bought a new position in shares of Natera during the 4th quarter worth approximately $41,000. Finally, Quent Capital LLC bought a new position in shares of Natera during the 3rd quarter worth approximately $46,000. Institutional investors own 99.90% of the company's stock.

Natera Company Profile

(Get Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.